omecamtiv mecarbil
Small moleculeexperimental
Omecamtiv mecarbil (INN), previously referred to as CK-1827452, is a cardiac-specific myosin activator. It is an experimental drug being studied for a potential role in the treatment of left ventricular systolic heart failure. — Wikipedia
Clinical trial activity
16 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
12
Phase 3
4
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT01380223)
Timeline
Indications
Mechanism of action
- Cardiac myosinACTIVATOR
Cardiac myosin activator
Selectively activates the S1 domain of cardiac myosin.
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1- Mol. weight
- 401.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOmecamtiv mecarbil ↗
- ChEMBLCHEMBL1800955 ↗
Also known as
- amg 423
- amg 423
- amg-423
- ck 1827452
- ck-1827452
- ck-1827452
- ck-1827452
- ck-1827452
- omecamtiv mecarbil
- omecamtiv mecarbil
- omecamtiv mecarbil
- omecamtiv mecarbil
- omecamtiv mecarbil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06736574 | Phase 3 | Dec 31, 2024 | Cytokinetics |
| NCT04464525 | Phase 3 | Dec 18, 2020 | Amgen |
| NCT04175808 | Phase 1 | Nov 14, 2019 | Amgen |
| NCT03759392 | Phase 3 | Apr 9, 2019 | Amgen, Cytokinetics, Servier |
| NCT02929329 | Phase 3 | Jan 6, 2017 | Amgen, Cytokinetics, Servier |
| NCT02695420 | Phase 2 | Apr 14, 2016 | Amgen |
| NCT02601001 | Phase 1 | Nov 1, 2015 | Amgen |
| NCT01786512 | Phase 2 | Feb 1, 2013 | Amgen, Cytokinetics |
| NCT01737866 | Phase 1 | Nov 1, 2012 | Amgen, Cytokinetics |
| NCT01300013 | Phase 2 | Apr 1, 2011 | Amgen, Cytokinetics |
| NCT01077167 | Phase 2 | Jul 1, 2010 | Amgen |
| NCT00941681 | Phase 2 | Apr 1, 2009 | Cytokinetics |
| NCT00748579 | Phase 2 | Sep 1, 2008 | Cytokinetics |
| NCT00682565 | Phase 2 | Apr 1, 2008 | Cytokinetics |
| NCT00624442 | Phase 2 | Apr 1, 2007 | Cytokinetics |
| NCT01380223 | Phase 1 | Aug 1, 2005 | Cytokinetics |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytokinetics | For profit | 11 | 6 | 3 | 2005 |
| Amgen | For profit | 10 | 10 | 3 | 2010 |
| Servier | For profit | 2 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1